Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis

Clinical Therapeutics

Volumn 30, Issue 3, 2008, Pages 429-442

  Massarotti, Elena M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

abatacept; CTLA 4Ig; patient reported outcomes; quality of life; rheumatoid arthritis

Indexed keywords

ABATACEPT; ANTIINFLAMMATORY AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; PLACEBO; PREDNISONE; STEROID;

ARTICLE; BIOSIS; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG WITHDRAWAL; EMBASE; HUMAN; MEDLINE; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HEALTH STATUS; HUMANS; IMMUNOCONJUGATES; PILOT PROJECTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 41649096507     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.03.002     Document Type: Article

References (45)

1. Lee D., and Weinblatt M. Rheumatoid arthritis. Lancet 358 (2001) 903-911
2. Goronzy J., and Weyland C. Rheumatoid arthritis: Epidemiology, pathology, and pathogenesis. In: Klippel J. (Ed). Primer on the Rheumatic Diseases. 12th ed. (2001), Arthritis Foundation, Atlanta, Ga 209-217
3. Arthritis Foundation survey (2005). http://www.arthritis.org/communities/chapters/GrtrChicago/PR/Press_Releases.asp#ra%20study [Arthritis Foundation Web site]. Accessed October 1, 2007
4. Fraenkel L., Bogardus S., Concato J., et al. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 63 (2004) 1372-1378
5. Wolfe F., and Michaud K. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: An investigation in 24,831 patients. J Rheumatol 31 (2004) 2115-2120
6. Carr A., Hewlett S., Hughes R., et al. Rheumatology outcomes: The patient's perspective. J Rheumatol 30 (2003) 880-883
7. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46 (2002) 328-346
8. Keystone E., Kavanaugh A., Sharp J., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50 (2004) 1400-1411
9. Smolen J., Aletaha D., and Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?. Arthritis Rheum 52 (2005) 2975-2983
10. Orencia (abatacept) [prescribing information] [Orencia Web site]
11. http://www.orencia.com Accessed October 1, 2007
12. Felson D., Anderson J., Boers M., et al., for the Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum 36 (1993) 729-740
13. Fransen J., Creemers M., and Van Riel P. Remission in rheumatoid arthritis: Agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43 (2004) 1252-1255
14. American College of Rheumatology, Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: The hybrid measure of American College of Rheumatology response. [published correction appears in Arthritis Rheum 2007;57:1574]. Arthritis Rheum 57 (2007) 189-190
15. Formulation of patient reported outcomes [Galen Research Web site]
16. http://www.galen-research.com/index.asp?sectionID=2subSectionID=10 Accessed October 1, 2007
17. WHO Constitution (1948), WHO, Geneva, Switzerland
18. Cella D. Functional Assessment of Chronic Illness Therapy (FACIT) [FACIT Web site]
19. www.facit.org Accessed October 1, 2007
20. The EuroQol Group (EQ-5D) [EQ-5D Web site]
21. www.euroqol.org Accessed October 1, 2007
22. Lubeck D. Patient-reported outcomes and their role in the assessment of rheumatoid arthritis. PharmacoEconomics 22 Suppl 1 (2004) 27-38
23. Stewart A., and Ware Jr. J. Measuring Functioning and Well Being: The Medical Outcomes Study Approach (1992), Duke University Press, Durham, NC
24. Wells G., Tugwell P., Kraag G., et al. Minimum important difference between patients with rheumatoid arthritis: The patient's perspective. J Rheumatol 20 (1993) 557-560
25. Kosinski M., Zhao S., Dedhiya S., et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 43 (2000) 1478-1487
26. Ware Jr. J. SF-36 health survey update. Spine 25 (2000) 3130-3139
27. Ware Jr JE. SF-36 Health Survey Update [SF-36 Web site]
28. http://www.sf-36.org/tools/SF36.shtml Accessed October 1, 2007
29. Fries J., Spitz P., Kraines R., and Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 23 (1980) 137-145
30. Wolfe F. Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): Analyses in 2491 rheumatoid arthritis patients following leflunomide initiation. J Rheumatol 28 (2001) 982-989
31. Bruce B., and Fries J. The Stanford Health Assessment Questionnaire: A review of its history, issues, progress, and documentation. J Rheumatol 30 (2003) 167-178
32. Bruce B., and Fries J. The Stanford Health Assessment Questionnaire: Dimensions and practical applications. Health and Quality of Life Outcomes 1 (2003) 20
33. Uhlig T., Haavardsholm E., and Kvien T. Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ (MHAQ) in patients with rheumatoid arthritis. Rheumatology 45 (2006) 454-458
34. Wells G., Li T., Maxwell L., et al. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol 34 (2007) 280-289
35. Mancuso C., Rincon M., Sayles W., and Paget S. Psychosocial variables and fatigue: A longitudinal study comparing individuals with rheumatoid arthritis and healthy controls. J Rheumatol 33 (2006) 1496-1502
36. Kremer J., Genant H., Moreland L., et al. Effects of abatacept in patients with methotrexateresistant active rheumatoid arthritis: A randomized trial. Ann Intern Med 144 (2006) 865-876
37. Kremer J., Westhovens R., Leon M., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349 (2003) 1907-1915
38. Kremer J., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebocontrolled trial. [published correction appears in Arthritis Rheum. 2005; 52:3321]. Arthritis Rheum 52 (2005) 2263-2271
39. Genovese M., Becker J., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. [published correction appears in N Engl J Med. 2005;353:2311]. N Engl J Med 353 (2005) 1114-1123
40. Moreland L., Alten R., Van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46 (2002) 1470-1479
41. Weinblatt M., Combe B., Covucci A., et al. Safety of the selective costimulation modulator abatacept in rheu matoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumaticdrugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 54 (2006) 2807-2816
42. Weinblatt M., Schiff M., Goldman A., et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial. Ann Rheum Dis 66 (2007) 228-234
43. Wolfe F. Fatigue assessments in rheumatoid arthritis: Comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 31 (2004) 1896-1902
44. Russell A., Wallenstein G., Li T., et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 66 (2007) 189-194
45. Emery P., Kosinski M., Li T., et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved healthrelated quality of life. J Rheumatol 33 (2006) 681-689